Skip to main content

Table 1 Comparison of RECIST version 1.1 and the Choi criteria

From: Early evaluation of sunitinib for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms via CT imaging: RECIST 1.1 or Choi Criteria?

 

RECIST version 1.1

Choi criteria

CR

Disappearance of all lesions

No new lesions

Disappearance of all lesions

No new lesions

PR

A decrease in sizea of ≥30%

A decrease in sizea of ≥10% or a decrease in tumor density (HU) of ≥15% in CT

No new lesions

No obvious progression of immeasurable disease

SD

Neither sufficient shrinkage to qualify for PR nor a sufficient increase to qualify for PD

Does not meet the criteria for CR, PR, or PD

No symptomatic deterioration attributable to tumor progression

PD

An increase in sizea of ≥20%

New lesions

New intratumoral nodules or increase in the size of the existing intratumoral nodules

An increase in tumor sizea of ≥10% and does not meet the criteria for PR based on tumor density (HU) in CT

New lesions

New intratumoral nodules or an increase in the size of the existing intratumoral nodules

  1. aSum of the diameters of the target lesions defined in RECIST version 1.1 [20]